[Predictive markers in gynaecological, prostate, and breast cancers]

Area of Science:

• Oncology
• Pathology
• Molecular Diagnostics

Background:

• Targeted therapies have significantly advanced oncology treatment for solid tumors.
• Pathological and molecular pathological diagnostics are increasingly vital in modern cancer care.
• Predictive biomarker testing is now a standard requirement for most solid tumors.

Purpose of the Study:

• To summarize essential molecular pathology tests for specific solid tumors.
• To align diagnostic practices with current clinical and pathological guidelines.
• To provide a resource for oncologists and pathologists regarding targeted therapy selection.

Main Methods:

• Review of current clinical and pathological guidelines.
• Identification of key molecular pathology tests for targeted therapies.
• Focus on gynecological tumors, prostate cancer, and breast cancer.

Main Results:

• Numerous targeted therapies are available for gynecological, prostate, and breast cancers.
• Specific molecular pathology tests are required for the effective use of these therapies.
• Guidelines emphasize the importance of predictive biomarker testing.

Conclusions:

• Molecular pathology testing is indispensable for guiding targeted therapy in oncology.
• Adherence to guidelines ensures appropriate biomarker testing for treatment selection.
• This review consolidates essential testing information for key cancer types.